Cocrystal Pharma Q3 net loss $4.9M; cash $13M; expects topline data from two studies soon

Cocrystal Pharma, Inc.

2024-Q3 EPS reported -$1.40

Net loss Q3 2024 of $4.9M ($0.49 per share) vs $4.2M ($0.41) in Q3 2023 which included $1.6M legal settlement.
Cash and cash equivalents $13.0M as of Sep 30, 2024, down from $26.4M at Dec 31, 2023; working capital $12.3M.
R&D expenses $3.2M (down from $4.2M); G&A $1.8M (stable).
Expects topline results from Phase 2a influenza A challenge study (CC-42344) by year end 2024.
Topline results from Phase 1 norovirus/coronavirus study (CDI-988) expected late 2024/early 2025; cash sufficient for 12 months.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.